Article Text

Download PDFPDF

AB0749 ARE THERE ANY DIFFERENCES IN THE EFFECTIVITY AND SAFETY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS ACCORDING THEIR GENDER?
  1. Rosa García1,
  2. Manuel Fernandez-Prada2,
  3. Arantxa Conesa3,
  4. Jose Campos Esteban4,
  5. Ana Urruticoechea-Arana5,
  6. Alejandro Olive6,
  7. Silvia Paredes7,
  8. Delia Taverner7,
  9. Carlos Gonzalez1,
  10. RENACER
  1. 1Hospital Virgen de la Victoria, Rheumatology, Málaga, Spain
  2. 2Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain
  3. 3Hospital General Universitari de Castelló, Rheumatology, Castelló de la Plana, Spain
  4. 4Hospital Universitario Puerta de Hierro, Rheumatology, Madrid, Spain
  5. 5Hospital Can Misses, Rheumatology, Eivissa, Spain
  6. 6Hospital Germans Trias i Pujol, Badalona, Spain
  7. 7Hospital Universitari Sant Joan de Reus, Reus, Spain
  8. 8Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain

Abstract

Background: Gender-related biochemical, hormonal and psychological factors could play an important role in the response to TNF blocker therapy in psoriatic arthritis (PsA). Scarce data are available analyzing differences in effectiveness and safety of the antiTNFs, and none in particular with Certolizumab Pegol (CZP) according to the gender.

Objectives: To evaluate the influence of the gender in the effectiveness and safety of CZP in the routine clinical setting in PsA patients.

Methods: Observational, national and muticentric cohort (approved by local ethical committee), PsA patients treated with CZP according to routine clinical practice were studied for 12 months. Clinical and disease characteristics and disease activity between gender were compared. Safety analysis: adverse events and withdrawn.

Results: 347 PsA patients were analyzed. No statistical differences were found between women and men at baseline in demographics, clinical variables, except for previous biologic treatment and ESR (Table 1). In both genders, a statistical significant decreased was observed after 1 year of CZP treatment in the following variables: DAS28(CRP); SJC; TJC; PGA (patient global ssesment);% patients with enthesitis, dactilytis and nail disease; but with no differences between females and males. Variables that influence the response at 12 months are: disease duration, CRP and TJC at baseline. Drug survival of CZP was 80.1%, and no differences were observed in gender. Adverse events related to CZP were observed in 9.5% and 19.9% withdrawn treatment: 12.4% due to lack of effectiveness, 4.0% due to intolerance and 3.5% other reasons.

Conclusion: CZP has shown to be effective and safe in PsA patient after a year of treatment in clinical practice regardless patient’s gender.

Abstract aB0749 Table 1

Baseline demographic, clinical and disease activity characteristics.

Abstract aB0749 Table 2.

CZP effectiveness at 1 year of treatment

Disclosure of interests: Rosa García : None declared, Manuel Fernandez-Prada: None declared, arantxa Conesa: None declared, Jose Campos Esteban: None declared, aNA URRUTICOECHEA-ARANA: None declared, alejandro Olive: None declared, SILVIA PAREDES Speakers bureau: Bristol, Roche, amgen, Pfiser, abbvie, lilly, UCB, Delia Taverner Speakers bureau: amgen, pfiser, Bristol, Lilly, Roche, Carlos Gonzalez Consultant for: Celgene, Gilead, Janssen, Merk, Novartis, Pfizer, Speakers bureau: Celgene, Roche, UCB

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.